lundi 3 février 2020

Onco Actu du 3 février 2020


1.1 BIOLOGIE - GÉNOME



Mutation’s role in blood cancers revealed by ideal team-up [Cold Spring Harbor Lab]











4.10 DÉP., DIAG. & PRONO. - POUMON



Lung cancer screening decision aid delivered through tobacco quitlines improves informed decision-making ’MD Anderson Cancer Center]











4.12 BIOPSIES LIQUIDES



These start-ups are racing to help doctors detect cancer early with a simple blood test [CNBC]










4.9 DÉP., DIAG. & PRONO. - SEIN



New View of the Brink of Cancer May Validate Preventive Mastectomy [DNA Science Blog]










PIK3CA-mutated Metastatic Breast Cancer [ESMO]











5.10 TRAITEMENTS - ESSAIS



Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer [Bayer]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Researchers identify possible new combination treatment for advanced melanoma [UCLA]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Resistant to CAR-T therapies? It's the cancer, not your immune system — study [EndPoints]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer [BMS]











GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma [GSK]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Not a kickback: Novartis’ Kymriah travel assistance program gets a green light from HHS [Fierce Pharma]











Are CAR T-Cell Therapies Worth the Costs? [ASH Clinical News]










5.2 PHARMA



EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer [Seattle Genetics]











5.2.1 PHARMA - PARTENARIATS



Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer [Onxeo]











5.2.6 PHARMA - BIOTECH



Black Diamond doubles in value hours into Nasdaq debut, marking hot start to the 2020 IPO run [EndPoints]











5.3 TRAITEMENTS - FDA, EMA,...



Hahn stresses importance of data, RWE in first all-hands meeting [EndPoints]











UK withdrawal from the EU on 31 January 2020 [EMA]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab) [Pfizer]











Bayer receives positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer [Bayer]











AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia [AbbVie]











Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020 [EMA]










6.1 OBSERVATION



Spike in US colorectal cancer rates from age 49 to 50 suggests many cases likely undiagnosed before screenings [Tulane University]











Fall in US cancer death rates: Time to pop the champagne? [EClinical Medicine]











6.10 POLITIQUES



What happens after Brexit and what could it mean for cancer? [Cancer Research UK]











6.4 MÉDICO-ÉCO



Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions [EClinical Medicine]











6.8 COMMUNICATION



Research on a roll: FDA ad police tackle cancer drugs on TV [Fierce Pharma]